Page "Antipsychotic" Paragraph 50

A review of the methods used in trials of antipsychotics, despite stating that the overall quality is " rather good ," reported issues with the selection of participants ( including that in schizophrenia trials up to 90 % of people who are generally suitable do not meet the elaborate inclusion and exclusion criteria, and that negative symptoms have not been properly assessed despite companies marketing the newer antipsychotics for these ); issues with the design of trials ( including pharmaceutical company funding of most of them, and inadequate experimental " blinding " so that trial participants could sometimes tell whether they were on placebo or not ); and issues with the assessment of outcomes ( including the use of a minimal reduction in scores to show " response ," lack of assessment of quality of life or recovery, a high rate of discontinuation, selective highlighting of favorable results in the abstracts of publications, and poor reporting of side-effects ).